View all financial news

Dolby Laboratories Reports Second Quarter Fiscal 2014 Financial Results

04/29/2014

SAN FRANCISCO--(BUSINESS WIRE)-- Dolby Laboratories, Inc. (NYSE:DLB) today announced the Company's financial results for the second quarter (Q2) of fiscal year 2014. For the second quarter, Dolby reported total revenue of $278.6 million, compared to $249.3 million for the second quarter of fiscal year 2013.

Second quarter GAAP net income was $75.9 million, or $0.73 per diluted share, compared to $61.9 million, or $0.60 per diluted share, for the second quarter of fiscal 2013. On a non-GAAP basis, second quarter net income was $91.7 million, or $0.88 per diluted share, compared to $76.4 million, or $0.74 per diluted share, for the second quarter of fiscal 2013. Dolby's non-GAAP measures are described and reconciled to the corresponding GAAP measures at the end of this release.

"We're pleased to report our second quarter results with revenues higher than forecast," said Kevin Yeaman, President and CEO, Dolby Laboratories. "Our broadcast business continues to outperform, and we are excited to work with great partners creating amazing consumer products such as the Sony PlayStation 4, Microsoft Xbox One, and the recently unveiled Amazon Fire TV."

Financial Outlook

Q3 2014

Dolby estimates that total revenue will range from $205 million to $215 million. Gross margin percentages are projected to range between approximately 91% to 92% on a GAAP basis and 92% to 93% on a non-GAAP basis.

Dolby anticipates that operating expenses will be between approximately $153 million and $158 million on a GAAP basis and between $135 million and $140 million on a non-GAAP basis.

Dolby expects diluted earnings per share to be between $0.24 and $0.29 on a GAAP basis and between $0.38 and $0.43 on a non-GAAP basis.

The Company estimates that its fiscal Q3 2014 effective tax rate will be between approximately 27% and 28% on both a GAAP and non-GAAP basis.

FISCAL YEAR 2014

Dolby anticipates that total revenue will range from $930 million to $950 million.

Dolby anticipates that operating expenses will be between approximately $611 million and $616 million on a GAAP basis and between $535 million and $540 million on a non-GAAP basis.

The Company's Conference Call Information

Members of Dolby management will lead a conference call open to all interested parties to discuss Q2 fiscal 2014 financial results for Dolby Laboratories at 2:00 p.m. PT (5:00 p.m. ET) on Tuesday, April 29, 2014. Access to the teleconference will be available over the Internet from http://investor.dolby.com/medialist.cfm or by dialing 1-888-599-4876. International callers can access the conference call at 1-913-312-1485.

A replay of the call will be available from 5:00 p.m. PT on Tuesday, April 29, 2014, until 9:00 p.m. PT on Tuesday, May 6, 2014, by dialing 1-877-870-5176 (international callers can access the replay by dialing 1-858-384-5517) and entering the confirmation code 1121212. An archived version of the teleconference will also be available on the Dolby Laboratories website, www.dolby.com.

Non-GAAP Financial Information

To supplement Dolby's financial statements presented on a GAAP basis, Dolby provides certain non-GAAP financial measures. These measures are adjusted to exclude amounts related to stock-based compensation, expense associated with dividend equivalents paid on restricted stock units, the amortization of intangibles from business combinations, restructuring charges, and the related tax impact of these items. Dolby presents non-GAAP financial measures in reporting its financial results to provide investors with an additional tool to evaluate Dolby's operating results in a manner that focuses on what Dolby's management believes to be its ongoing business operations. Dolby's management believes it is useful for itself and investors to review both GAAP and non-GAAP measures in order to assess the performance of Dolby's business for planning and forecasting in subsequent periods. Dolby's management does not itself, nor does it suggest that investors should consider non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Whenever Dolby uses non-GAAP financial measures, it provides a reconciliation of the non-GAAP financial measures to the most closely applicable GAAP financial measures. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as detailed above. Investors are also encouraged to review Dolby's GAAP financial statements as reported in its US Securities and Exchange Commission (SEC) filings. A reconciliation between GAAP and non-GAAP financial measures is provided at the end of this press release and on Dolby's investor relations website at http://investor.dolby.com/medialist.cfm.

Forward-Looking Statements

Certain statements in this press release, including, but not limited to, statements relating to Dolby's expected financial results for Q3 2014 and fiscal 2014 are "forward-looking statements" that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations, and as a result of certain risks and uncertainties, actual results may differ materially from those projected. The following important factors, without limitation, could cause actual results to differ materially from those in the forward-looking statements: risks associated with trends in the markets in which Dolby operates, including the personal computer, DVD, and Blu-ray Disc™, broadcast, consumer electronics, gaming, mobile, and automobile markets; the loss of, or reduction in sales by, a key customer or licensee; pricing pressures; risks associated with the rate at which OEMs include optical disc playback in Windows® 8 devices and the rate of consumer adoption of Windows operating systems; risks that a shift from disc-based media to online media content could result in fewer devices with Dolby® technologies; risks associated with the effects of macroeconomic conditions, including trends in consumer spending; risks relating to the expiration of patents; the timing of Dolby's receipt of royalty reports and payments from its licensees; Dolby's accuracy of calculation of royalties due to its licensors; Dolby's ability to develop, maintain, and strengthen relationships with industry participants; Dolby's ability to develop and deliver innovative technologies in response to new and growing markets in the entertainment industry; competitive risks; risks associated with conducting business in China and other countries that have historically limited recognition and enforcement of intellectual property and contractual rights; risks associated with the health of the motion picture industry generally; the development and growth of the market for digital cinema and digital 3D and Dolby's ability to successfully penetrate this market; Dolby's ability to expand its business generally, and to expand its business beyond sound technologies to other technologies related to digital entertainment delivery; risks associated with acquiring and successfully integrating businesses or technologies; and other risks detailed in Dolby's US Securities and Exchange Commission filings and reports, including the risks identified under the section captioned "Risk Factors" in its most recent quarterly report on Form 10-Q. Dolby disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

About Dolby Laboratories

Dolby Laboratories (NYSE:DLB) creates audio, video, and voice technologies that transform entertainment and communications in mobile devices, at the cinema, at home, and at work. For nearly 50 years, sight and sound experiences have become more vibrant, clear, and powerful in Dolby. For more information, please visit www.dolby.com.

Dolby and the double-D symbol are registered trademarks of Dolby Laboratories. All other trademarks remain the property of their respective owners. S14/27979 DLB-F

 
DOLBY LABORATORIES, INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

         
    Fiscal Quarter Ended   Fiscal Year-To-Date Ended
    March 28,
2014
  March 29,
2013
  March 28,
2014
  March 29,
2013
Revenue:                
Licensing   $ 258,616     $ 226,455     $ 464,276     $ 431,331  
Products   14,563     17,726     32,667     43,224  
Services   5,413     5,165     12,926     11,393  
Total revenue   278,592     249,346     509,869     485,948  
                 
Cost of revenue:                
Cost of licensing   3,742     6,409     7,743     9,489  
Cost of products   10,293     13,206     24,081     31,695  
Cost of services   3,470     3,668     7,063     7,704  
Total cost of revenue   17,505     23,283     38,887     48,888  
                 
Gross margin   261,087     226,063     470,982     437,060  
                 
Operating expenses:                
Research and development   44,798     41,948     89,261     84,384  
Sales and marketing   64,828     58,130     125,207     116,551  
General and administrative   46,457     41,803     88,365     84,911  
Restructuring charges   86         3,301      
Total operating expenses   156,169     141,881     306,134     285,846  
                 
Operating income   104,918     84,182     164,848     151,214  
                 
Other income/expense:                
Interest income   920     904     1,574     2,243  
Interest expense   (93 )   (402 )   (205 )   (427 )
Other income/(expense), net   (2,823 )   188     (2,594 )   901  
Total other income/expense   (1,996 )   690     (1,225 )   2,717  
                 
Income before income taxes   102,922     84,872     163,623     153,931  
Provision for income taxes   (26,373 )   (22,633 )   (41,828 )   (40,215 )
Net income including controlling interest   76,549     62,239     121,795     113,716  
Less: net (income) attributable to controlling interest   (681 )   (328 )   (1,412 )   (456 )
Net income attributable to Dolby Laboratories, Inc.   $ 75,868     $ 61,911     $ 120,383     $ 113,260  
                 
Net Income Per Share:                
Basic   $ 0.74     $ 0.61     $ 1.18     $ 1.11  
Diluted   $ 0.73     $ 0.60     $ 1.16     $ 1.10  
Weighted-Average Shares Outstanding:                
Basic   102,291     101,638     102,021     102,000  
Diluted   103,934     102,680     103,460     102,980  

 

 
DOLBY LABORATORIES, INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

         
    March 28,
2014
  September 27,
2013
ASSETS   (unaudited)    
Current assets:        
Cash and cash equivalents   $ 568,899     $ 454,397
Restricted cash   3,344     3,175
Short-term investments   169,082     140,267
Accounts receivable, net   109,143     97,460
Inventories   9,569     10,093
Deferred taxes   82,980     84,238
Prepaid expenses and other current assets   24,377     28,949
Total current assets   967,394     818,579
Long-term investments   304,376     306,338
Property, plant and equipment, net   242,970     242,917
Intangible assets, net   46,772     41,315
Goodwill   279,871     279,724
Deferred taxes   44,877     37,434
Other non-current assets   10,295     11,638
Total assets   $ 1,896,555     $ 1,737,945
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
Accounts payable   $ 10,312     $ 10,695
Accrued liabilities   144,382     137,795
Income taxes payable   9,148     3,394
Deferred revenue   12,640     20,931
Total current liabilities   176,482     172,815
Long-term deferred revenue   20,178     19,663
Other non-current liabilities   46,713     45,441
Total liabilities   243,373     237,919
         
Stockholders' equity:        
Class A common stock   50     47
Class B common stock   53     55
Additional paid-in capital   49,074     18,812
Retained earnings   1,574,765     1,454,382
Accumulated other comprehensive income   8,694     7,814
Total stockholders' equity - Dolby Laboratories, Inc.   1,632,636     1,481,110
Controlling interest   20,546     18,916
Total stockholders' equity   1,653,182     1,500,026
Total liabilities and stockholders' equity   $ 1,896,555     $ 1,737,945

 

 
DOLBY LABORATORIES, INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

         
    Fiscal Quarter Ended   Fiscal Year-To-Date Ended
    March 28,
2014
  March 29,
2013
  March 28,
2014
  March 29,
2013
Operating activities:                
Net income including controlling interest   $ 76,549     $ 62,239     $ 121,795     $ 113,716  
Adjustments to reconcile net income to net cash provided by operating activities:                
Depreciation and amortization   12,705     13,291     25,114     26,420  
Stock-based compensation   17,753     14,945     32,807     32,649  
Amortization of premium on investments   2,328     2,159     4,594     5,953  
Excess tax benefit from exercise of stock options   (552 )   (180 )   (1,562 )   (649 )
Provision for doubtful accounts   133     449     507     270  
Deferred income taxes   (4,980 )   (7,950 )   (6,302 )   (10,577 )
Other non-cash items affecting net income   2,838     (181 )   2,943     (872 )
Changes in operating assets and liabilities:                
Accounts receivable   (33,334 )   (39,884 )   (12,186 )   (47,948 )
Inventories   (585 )   5,419     1,640     (754 )
Prepaid expenses and other assets   492     (4,787 )   (1,139 )   4,129  
Accounts payable and other liabilities   22,033     17,756     5,337     (2,142 )
Income taxes, net   8,591     (5,090 )   13,386     4,422  
Deferred revenue   (1,879 )   (1,846 )   (7,776 )   (1,989 )
Other non-current liabilities   46     416     262     1,428  
Net cash provided by operating activities   102,138     56,756     179,420     124,056  
                 
Investing activities:                
Purchase of investments   (76,113 )   (118,862 )   (178,830 )   (325,997 )
Proceeds from sales of investment securities   35,998     78,037     63,424     467,105  
Proceeds from maturities of investment securities   34,663     13,625     81,402     64,950  
Purchases of property, plant and equipment   (8,905 )   (5,447 )   (17,872 )   (12,164 )
Purchases of intangible assets   (12,400 )   (2 )   (12,400 )   (4,050 )
Proceeds from sale of property, plant and equipment and assets held for sale       357     42     376  
Change in restricted cash   5     (937 )   (169 )   (1,228 )
Net cash provided by/(used in) investing activities   (26,752 )   (33,229 )   (64,403 )   188,992  
                 
Financing activities:                
Proceeds from issuance of common stock   9,337     2,700     17,464     7,202  
Repurchase of common stock       (11,477 )   (11,660 )   (65,433 )
Payment of cash dividend               (408,206 )
Distribution to controlling interest               (5,039 )
Excess tax benefit from the exercise of stock options   552     180     1,562     649  
Shares repurchased for tax withholdings on vesting of restricted stock   (1,631 )   (1,496 )   (8,358 )   (5,132 )
Net cash provided by/(used) in financing activities   8,258     (10,093 )   (992 )   (475,959 )
Effect of foreign exchange rate changes on cash and cash equivalents   615     (1,119 )   477     (1,181 )
Net increase/(decrease) in cash and cash equivalents   84,259     12,315     114,502     (164,092 )
Cash and cash equivalents at beginning of period   484,640     316,193     454,397     492,600  
Cash and cash equivalents at end of period   $ 568,899     $ 328,508     $ 568,899     $ 328,508  

 

 
GAAP to Non-GAAP Reconciliations
(In millions, except per share data)
 
The following tables present the Company's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the second quarter of fiscal 2014 and 2013:
 
Net income:   Fiscal Quarter Ended
    March 28,
2014
  March 29,
2013
GAAP net income   $ 75.9     $ 61.9  
Stock-based compensation   17.7     14.9  
RSU dividend equivalent   0.9     2.2  
Amortization of acquired intangibles   2.8     3.4  
Restructuring charges, net   0.1      
Income tax adjustments   (5.7 )   (6.0 )
Non-GAAP net income   $ 91.7     $ 76.4  
             
Diluted earnings per share:   Fiscal Quarter Ended
    March 28,
2014
  March 29,
2013
GAAP diluted earnings per share   $ 0.73     $ 0.60  
Stock-based compensation   0.17     0.15  
RSU dividend equivalent   0.01     0.02  
Amortization of acquired intangibles   0.03     0.03  
Restructuring charges, net        
Income tax adjustments   (0.06 )   (0.06 )
Non-GAAP diluted earnings per share   $ 0.88     $ 0.74  
             
Shares used in computing diluted earnings per share (in millions)   104     103  
             
The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial amounts for the third quarter of fiscal 2014 and fiscal year 2014 included in this release:
 
Gross margin:   Q3 2014      
GAAP gross margin (low - high end of range)  

91% - 92

%

     
Stock-based compensation   0.2 %      
Amortization of acquired intangibles   0.8 %      
Non-GAAP gross margin (low - high end of range)  

92% - 93

%

     
             
Operating expenses:   Q3 2014   Fiscal 2014
GAAP operating expenses (low - high end of range)   $153 - $158     $611 - $616  
Stock-based compensation   (16 )   (66 )
RSU dividend equivalent   (1 )   (3 )
Amortization of acquired intangibles   (1 )   (4 )
Restructuring charges, net       (3 )
Non-GAAP operating expenses (low - high end of range)   $135 - $140     $535 - $540  
             
Diluted earnings per share:   Q3 2014
    Low   High
GAAP diluted earnings per share   $ 0.24     $ 0.29  
Stock-based compensation   0.16     0.16  
RSU dividend equivalent   0.01     0.01  
Amortization of acquired intangibles   0.03     0.03  
Income tax adjustments   (0.06 )   (0.06 )
Non-GAAP diluted earnings per share   $ 0.38     $ 0.43  
             
Shares used in computing diluted earnings per share (in millions)   103     103  

 

Dolby Laboratories
Investor Contact:
Elena Carr, 415-645-5583
investor@dolby.com
Media Contact:
Sean Durkin, 415-645-5176
news@dolby.com

Source: Dolby Laboratories, Inc.

Multimedia Files:

Categories: Press Releases
View all news